COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 11/03/22
COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of MedicineGlobeNewsWire • 11/03/22
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022GlobeNewsWire • 10/26/22
COMPASS Pathways PLC Sponsored ADR (CMPS) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 10/25/22
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets DayGlobeNewsWire • 10/12/22
COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health SummitGlobeNewsWire • 09/19/22
One Mind Announces the Winners of the 2022 Rising Star Awards for Mental Health ResearchBusiness Wire • 08/24/22
Wall Street Analysts See a 289% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?Zacks Investment Research • 08/08/22
COMPASS Pathways plc's (CMPS) CEO George Goldsmith on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
COMPASS Pathways plc announces second quarter 2022 financial results and business highlightsGlobeNewsWire • 08/04/22
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosaGlobeNewsWire • 07/28/22